Bruno Medeiros
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Hematology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr CC2329 MC 5821 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 724-5203
Professional Overview
Clinical Focus
- Cancer> Hematology
- Hematology
- Acute leukemia
Administrative Appointments
- Director, Stanford Hospital Hematology Inpatient service (2011 - 2013)
- Director, Stanford Acute Leukemia Clinical Research Program (2009 - 2013)
- Panel member adult oncology committee, National comprehensive cancer network (2010 - 2013)
- Acute Leukemia Panel Member, Southwest Oncology Group (SWOG) (2007 - 2013)
- Panel Member Multiple Myeloma Committee, National Comprehensive Cancer Network (2007 - 2011)
Professional Education
| Fellowship: | University of Colorado Health Science Center CO (2005) |
| Fellowship: | Acute leukemia, Princess Margaret Hospital - University of Toronto (2006) |
| Board Certification: | Hematology, American Board of Internal Medicine (2006) |
| Board Certification: | Medical Oncology, American Board of Internal Medicine (2005) |
| Residency: | University of Colorado Health Science Center CO (2002) |
| Internship: | University of Connecticut Health Center CT (2000) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
My clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.
Clinical Trials
- Recruiting S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Recruiting A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
- Not Recruiting Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Not Recruiting Phase I/II of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia
- Not Recruiting Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Publications
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2013; (4): 591-6
- Blood consult: monosomal karyotype acute myeloid leukemia. Blood. 2012; (24): 5659-60
- Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012; (9): 1401-4
- Impact of residual normal metaphases in core binding factor acute myeloid leukemia. Cancer. 2012; (9): 2420-3
- Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012; (5): 893-901
- Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol. 2012; (1): 45-50
Help
Trial Administration